Skip to content

Is the AMH Intrafollicular Level a Predictor of the Ploidy Status of the Blastocyst?

Is the AMH Intrafollicular Level a Predictor of the Ploidy Status of the Blastocyst? A Prospective Study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05837325
Enrollment
300
Registered
2023-05-01
Start date
2023-05-23
Completion date
2026-12-31
Last updated
2025-10-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility, Female, Infertility

Keywords

Estradiol, FSH, LH, AMH, Ploidy, Chromosomes, Infertility, Progesterone, Inhibin B

Brief summary

To investigate, whether on the day of egg retrieval, after ovarian stimulation for ICSI (intracytoplasmic sperm injection), there is a correlation between the intrafollicular AMH (Anti-Müllerian hormone) levels and the ploidy status of the blastocyst.

Detailed description

In clinical practice, AMH is used as a diagnostic and/or prognostic marker in women in association with ovulation induction and in various pathophysiological conditions. This study looks to investigate if the hormonal environment that surrounds an oocyte has an impact on the ploidy status of the blastocyst. Nowadays, using NGS (Next Generation Sequencing) platform for analysis of 23 pairs of chromosomes for Preimplantation Genetic Testing on blastocysts, the ploidy status of the embryo is more adequately assessed. Furthermore, embryo culture to blastocyst will provide further information about embryo quality and possibilities of implantation. To have complete information between the serum hormones, follicular hormones, embryo development and ploidy will provide to clinicians, embryologist and patients further information on embryo selection and adequate ovarian stimulation protocols. The database will be exported from the clinical information manager, VRepro, to a table in excel format through a database-based query system. The exported data will be duly codified to protect the clinical and personal information of the participants. Prior to the statistical study, an exploratory data analysis will be carried out to review the quality of the information extracted.

Interventions

PROCEDUREOocyte Pick Up - Out of Study

Aspiration of follicles. search for the oocyte(s) All oocytes are grouped in one dish.

PROCEDUREDenudation - Out of Study

All oocytes are denuded together. Maturational stages are recorded.

PROCEDUREICSI

One oocyte injected at a time.

PROCEDURECulture

One embryo per culture drop. Individual follow-up of the embryo development.

GENETICBiopsy

One embryo per culture drop.

PROCEDUREVitrification

One embryo per vitrification straw.

PROCEDUREOPU - Study Group

Measure the size of the follicle and aspirate only one follicle and flush. The needle before moving to the second ovary. Oocyte included in the study will be cultured separately (each ovary separately too).

PROCEDUREDenudation - Study Group

Oocyte included in the study will be denuded separately. Maturational stages are recorded per follicle.

Sponsors

ART Fertility Clinics LLC
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

* At least one follicle from each ovary at day of trigger * Age from 18 to 40 years old * Normal menstrual cycle of 25-35 days * Poor, normal and high response will be included * First follicle punctured from each ovary will be consider for inclusion: if the COC (Cumulus Oocyte Complex) is present in clear FF (Follicular fluid), the FF will be collected separately for further analysis and the oocyte included in the study

Exclusion criteria

* Very hematic follicular fluid * If the COC is not found in the follicular fluid * Azoospermia * Known chromosomal abnormalities * Severe OAT (Oligoasthenoteratozoospermia)

Design outcomes

Primary

MeasureTime frameDescription
Oocyte maturity1 dayCalculated as percentage transformation of an oocyte from prophase I to metaphase II
Fertilization1 dayPercentage of mature oocytes - metaphase II (MII) that become 2 pronucleii embryos (2PN)
Blastulation1 dayAbility of the embryo to form a cavity (=to blastulate) 114-118 hours post ICSI. Number of blastocysts divided by the number of 2PN
Blastocyst quality6 daysFour Embryo Quality Scores (EQ1, 2, 3, 4) based on the expansion stage of the blastocyst, the grade of the inner cell mass and the grade of the trophectoderm.
Ploidy status14 daysDetermined after biopsy of trophectoderm cells, taken from the blastocyst on day 5, 6 or 7 from development
Mitochondria status14 daysMeasured as mtDNA ratio, the ratio of mitochondrial DNA (mtDNA) read counts to autosomal (chromosome 1-22) DNA read counts

Secondary

MeasureTime frameDescription
AMH in serum day of OPU1 dayTo evaluate if there is an association between the levels of serum AMH on day 2-3 of the stimulation, AMH day of OPU and the intra-follicular AMH.
FSH in serum day of OPU1 dayTo evaluate if there is an association between serum FSH on day 2-3 of the stimulation, serum FSH day of OPU and the intra-follicular FSH.
LH in serum day of OPU1 dayTo evaluate if there is an association between serum LH on day 2-3 of the stimulation, serum LH day of OPU and the intra-follicular LH.
E2 in serum day of OPU1 dayTo evaluate if there is an association between serum E2 on day 2-3 of the stimulation, serum E2 day of OPU and the intra-follicular E2.
P4 in serum day of OPU1 dayTo evaluate if there is an association between serum P4 on day 2-3 of the stimulation, serum P4 day of OPU and the intra-follicular P4.
Inhibin B in serum day of OPU1 dayTo evaluate if there is an association between serum Inhibin B on day 2-3 of the stimulation, serum Inhibin B day of OPU and the intra-follicular Inhibin B.
E2 in the follicular fluid.1 dayTo evaluate if there is an association between serum E2 on day 2-3 of the stimulation, serum E2 day of OPU and the intra-follicular E2.
FSH in serum day of day 2/3 of stimulation.1 dayTo evaluate if there is an association between serum FSH on day 2-3 of the stimulation, serum FSH day of OPU and the intra-follicular FSH.
LH in serum day of day 2/3 of stimulation.1 dayTo evaluate if there is an association between serum LH on day 2-3 of the stimulation, serum LH day of OPU and the intra-follicular LH.
E2 in serum day of day 2/3 of stimulation.1 dayTo evaluate if there is an association between serum E2 on day 2-3 of the stimulation, serum E2 day of OPU and the intra-follicular E2.
P4 in serum day of day 2/3 of stimulation.1 dayTo evaluate if there is an association between serum P4 on day 2-3 of the stimulation, serum P4 day of OPU and the intra-follicular P4.
Inhibin B in serum day of day 2/3 of stimulation.1 dayTo evaluate if there is an association between serum Inhibin B on day 2-3 of the stimulation, serum Inhibin B day of OPU and the intra-follicular Inhibin B.
AMH in serum day of day 2/3 of stimulation.1 dayTo evaluate if there is an association between the levels of serum AMH on day 2-3 of the stimulation, AMH day of OPU and the intra-follicular AMH.
AMH in the follicular fluid.1 dayTo evaluate if there is an association between the levels of serum AMH on day 2-3 of the stimulation, AMH day of OPU and the intra-follicular AMH.
FSH in the follicular fluid.1 dayTo evaluate if there is an association between serum FSH on day 2-3 of the stimulation, serum FSH day of OPU and the intra-follicular FSH.
LH in the follicular fluid.1 dayTo evaluate if there is an association between serum LH on day 2-3 of the stimulation, serum LH day of OPU and the intra-follicular LH.
P4 in the follicular fluid.1 dayTo evaluate if there is an association between serum P4 on day 2-3 of the stimulation, serum P4 day of OPU and the intra-follicular P4.
Inhibin B in the follicular fluid.1 dayTo evaluate if there is an association between serum Inhibin B on day 2-3 of the stimulation, serum Inhibin B day of OPU and the intra-follicular Inhibin B.

Countries

United Arab Emirates

Contacts

Primary ContactBarbara Lawrenz, PhD
barbara.lawrenz@artfertilityclinics.com0097126528000
Backup ContactSuzan Samir
suzan.samir@artfertilityclinics.com0097126528000

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026